Further examination in dual‐xenograft models indicated that locoregional administration of anti‐GPC3 CAR‐T cells exhibited significantly enhanced efficacy compared to systemic delivery, leading to substantial inhibition of tumour growth in both orthotopic and extrahepatic HCC xenografts. This evidence concerns the gene GPC3 and hepatocellular carcinoma.